deal finish line step state away
solid results/busi clarif indic thesi track
hypothet list box need check
busi aetna deal think box check result
compani beat ebit expect segment led ep beat
deal remain firmli track manag commentari around activ
dialogu five remain state includ agreement california pave
way deal final shift focu opportun new
entiti also think manag commentari around opportun new
compani post-deal close welcom addit call display vast
opportun integr pbm/insurer/pharmacy/car deliveri compani
attack all-in quarter re-affirmed underli thesi total busi well
strateg potenti cvs-aetna reiter buy rate increas
po use price-to-earnings multipl
ep increment synergi opportun
maintain ep beat off-set slight aet time
dilut increas ep driven strong
perform increment cost save opportun post-aetna acquisit in-lin
increas view synergi exceed origin target
estim everi increment synergi yield ep
upcom event catalyst
importantli deal close target pre-thanksgiv look
increment data point remain five state prior deal approv on-going
dc headlin could also impact share includ comment manufactur rebat
chang medicar part b/part item addit amazon
purchas pharmaci asset close transact well increment
commentari amazon pharmaci plan could impact share final
think post-deal close expect manag activ engag
invest commun includ confer visit highly-anticip
new compani analyst day june nyc
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
store
outsid
store futur
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest healthcar compani
unit state provid retail mail
specialti pharmaci dispens servic
pharmaci benefit upon complet
acquisit aetna would becom one
vertic integr publicli trade
healthcar compani base
buy rate driven transform
vertic integr aetna assum deal
close stabl free cash flow appeal
valuat think compani deal aetna
provid ampl short-term long-term synergi
opportun provid clear way extract
valu retail franchis stabl
free cash flow three busi
allow compani gener outsiz
return equiti next year
aet result solid remain excit opportun
state approv left well road remain five state
execut synergi target exceed initi goal
focu reposit busi
one earli target manag five target chronic diseas
also plan optimize/expand primari care within minuteclin
first concept store run earli pilot clinic offer
prior roll broadli
drive enterpris valu medic cost save membership growth
increas custom satisfact expand custom valu open platform
exceed element guidanc quarter
leverag post-deal close plan de-lev remain unchang
net-new busi includ medicar part
work client consult new simpler pbm econom model
retail rx market share
continu see challeng skill nurs facil space pharmaci
long-term opportun assist live independ busi
work shift target market
pbm oper profit trend lower end rang retail/ltc oper
profit trend solidli within rang
issu share deal close
chang inter-compani elimin
deal slightli dilut base time deal
give guidanc call deal close
updat accret estim
view remain similar confid achiev target
want chang discuss focu drug mix
still see opportun grow share particularli integr
move toward performance-bas
ny activ product discuss
ca reach agreement materi term w/state final
nj last state hear yesterday
move piec
tailwind retail script growth net posit sell season
headwind price reimburs pressur lower level
unknown regulatori chang hh
aetna membership growth futur outlook
view combin two compani growth opportun
infrastructur rel current footprint
capital-expenditure two compani
chang store shift invest
driver margin pressur
success medicar part
synergi target flow
synergi net-synergi includ plan invest
chang initi baselin aet accret
base longer valid given tax reform invest
chang whatsoev transact
propos chang part part impact
excit opportun play bigger role market
season segment guidanc
cost ramp plan chang view
earli give color
teladoc partnership impact minuteclin strategi
roll state state
expand reach scope clinic
prefer store build-out
complet open partnership compani work
less movement year like due merger
retent happi
earli comment rfp activ sinc still gear
come
pleas progress program far
alway cost focu organ
price object base ep estim multipl
five-year averag absolut basi toward lower end
histor rang also repres bigger discount vs
last five year discount reflect margin pressur across core pharmaci
servic retail pharmaci segment uncertainti around drug price
downsid risk po risk amazon anoth disrupt forc enter
suppli chain failur close aetna transact close gener expect
synergi aetna transact grow competit risk pharmaci benefit
market slow prescription/insur trend upsid risk po
potenti prescript volum pickup faster stronger expect synergi
aetna improv front-end perform
michael cherni herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
